This then raises the question of whether treatment with phosphate-binding agents could improve outcome by lowering the FGF-23 levels in patients with earlier and later stages of CKD, as suggested recently,(70–72) and whether additional treatment options could be envisioned that reduce potential “off-target” effects of FGF-23. The gene discussed is FGF23; the disease is chronic kidney disease.